ANNOUNCEMENT

NOBEL PRIZE 2026

This year's laureates, their fields, and the discoveries that earned them the prize.Live nowSee the winners
Moonbase
← Back to Awards
NIHNATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES

Driving next generation UPR inhibitory kinase inhibitors for T1D

Active
Institution
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA
Principal investigator
Feroz R Papa
Funding
$816K
Duration
2025–2029
Open portfolio

Moonbase score

Still being scored

Abstract

PROJECT SUMMARY/ABSTRACT Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by hyperglycemia due to progressive immune-mediated destruction of pancreatic beta cells. Recent work from our laboratories has shown that hyperactivation of the unfolded protein response (UPR) to ER stress in the immune-targeted beta cells may be a critical early event in the development of T1D. We have developed novel pharmacological reagents called ‘PAIR’s that allow us to manipulate components of the UPR. Importantly, first-generation versions of small molecules delivered to NOD mice can efficaciously prevent and even reverse diabetes in this T1D model. Thus, in this collaborative grant we will capitalize on the complementary expertise of the investigators to optimize these next-generation “PAIR” molecules for potency and selectivity, conduct proof-of-concept studies using human islets (ex vivo and in transplanted mice), and perform key enabling steps needed to advance these candidates further into the clinic for treating human patients with T1D.

Research team

  • Dustin J MalyPI
  • Feroz R PapaPI

LOADING MOONBASE SCORE

NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESU01Special Emphasis Panel[ZDK1 GRB-J (J2)]response uprabstract typepairnod miceuprhuman isletsbeta cellsbeta

Questions for UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

Answered by the team behind this research.

No questions yet. Sign in to ask the first one

Related grants

Same researchers, same institution, same topic, scored first.